Lukas Krejcik

Title: Innovations of Lukas Krejcik

Introduction

Lukas Krejcik is a notable inventor based in Praha-Vinor, Czech Republic. He has made significant contributions to the field of pharmaceuticals, particularly in the development of stable polymorphs and new salts for medicinal compounds. With a total of two patents to his name, Krejcik's work is essential for advancing treatments for various medical conditions.

Latest Patents

Krejcik's latest patents include a stable polymorph of the salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-anime with L-tartaric acid. This stable polymorph, known as Form Z1, is particularly suitable for the active pharmaceutical ingredient intended for the treatment of type 2 diabetes. Additionally, he has developed new salts of desvenlafaxine with oxalic acid, including the hydrogen oxalate and hemioxalate forms, which are crucial for enhancing the efficacy of this medication.

Career Highlights

Throughout his career, Krejcik has worked with prominent companies in the pharmaceutical industry, including Zentiva and Sanofi. His experience in these organizations has allowed him to refine his skills and contribute to significant advancements in drug formulation and development.

Collaborations

Krejcik has collaborated with notable colleagues such as Jindrich Richter and Petr Lehnert. These partnerships have fostered innovation and have been instrumental in the successful development of his patented inventions.

Conclusion

Lukas Krejcik's contributions to the pharmaceutical field through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the development of effective treatments for various health conditions.